Background
Lexmark manufactured and sold printer toner cartridges in two ways: (1) “Regular Cartridges” sold at full price, and (2) “Return Program Cartridges” sold at a discount with a single-use restriction — the purchaser agreed not to reuse or resell the cartridge. Impression Products collected and refurbished used Lexmark cartridges — both domestic Return Program cartridges and cartridges sold abroad — and resold them in the United States. Lexmark sued for patent infringement, arguing that: (a) the single-use restriction in the Return Program license survived the sale and patent exhaustion did not apply, and (b) foreign sales did not exhaust U.S. patent rights at all.
The Federal Circuit, sitting en banc, ruled in Lexmark’s favor on both issues — holding that conditional domestic sales could preserve patent rights beyond the sale (if the restriction was clearly communicated), and that foreign authorized sales did not exhaust U.S. patent rights. Impression Products sought certiorari.
The Court’s Holding
The Supreme Court reversed on both issues. On domestic exhaustion: once a patent holder makes an authorized sale of a patented item, all patent rights in that item are exhausted — regardless of any post-sale restrictions the seller attempted to impose. A condition in a sales agreement is a contractual matter (enforceable through contract law), not a patent matter; the patent right itself is exhausted by the authorized sale. Patent law does not permit the patent holder to continue exercising patent rights after an authorized sale to control downstream use or resale.
On international exhaustion: authorized foreign sales also exhaust U.S. patent rights. The Court held that once a patent holder decides to sell a patented item abroad, it receives value for the sale and loses the ability to assert patent rights against downstream purchasers who import those items into the United States. This overruled the Federal Circuit’s rule that U.S. patents survived foreign authorized sales and aligned patent exhaustion with the copyright first sale doctrine as interpreted in Kirtsaeng v. John Wiley (2013).
Key Takeaways
- Patent exhaustion is absolute upon any authorized sale — domestic or foreign — of a patented item: the patent holder cannot use patent law to enforce post-sale restrictions on downstream use or resale of the item.
- Post-sale restrictions in sales contracts may still be enforceable as contract law — but violating them is a breach of contract, not patent infringement.
- Foreign authorized sales exhaust U.S. patent rights in the sold item, enabling parallel importation of genuine goods sold abroad without patent infringement liability.
- Companies relying on patent rights to maintain price discrimination between domestic and foreign markets — selling at higher prices domestically and lower prices abroad — lost an important tool for preventing parallel imports after Impression Products.
Why It Matters
Impression Products v. Lexmark was one of the most significant patent exhaustion decisions in decades, with major commercial implications for industries from printer supplies to pharmaceuticals to consumer electronics. The ruling confirmed that authorized sales — anywhere in the world — end the patent right in the sold item, limiting patent holders’ ability to use IP rights as a substitute for contract restrictions on downstream use and resale.
For the pharmaceutical industry, the decision raised concerns about parallel importation of patented drugs sold at lower prices in foreign markets. For consumer electronics and technology companies, it affected the viability of regional pricing strategies. The decision also reinforced the long-standing principle that patent rights, once exercised through authorized sale, should not be used to create vertically integrated control over downstream commerce — a principle rooted in the historic resistance to price maintenance and monopoly control over secondary markets.